An Open-Label, Phase III Study to Assess the Efficacy and Safety of Cysteamine Ophthalmic Solution 0.55% in Japanese Cystinosis Patients
Nobuhiro Goi, Fumino Iwata, Yoko Sugihara, Shingo Higa, Taiichiro Chikama · 2024
Read An Open-Label, Phase III Study to Assess the Efficacy and Safety of Cysteamine Ophthalmic Solution 0.55% in Japanese Cystinosis Patients by Nobuhiro Goi, Fumino Iwata, Yoko Sugihara, Shingo Higa, Taiichiro Chikama (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11606150.txt.
Description
Nobuhiro Goi and four colleagues published a drug study in two thousand twenty-four on eye drops for a rare disease called cystinosis. In this disease, cystine crystals build up in the cornea and make light painful. The study tested cysteamine drops over a year in Japanese patients.
Six patients used the drops for about fourteen months on average. Microscope scores for crystal load trended downward in every cornea layer. Most patients reported at least one step of relief from light sensitivity. Side effects were common but mild, with a tingling feeling reported most often. No serious side effects or deaths occurred. The authors judge the drops effective and well tolerated for this tiny group.
Catalog record
| CREATOR | Nobuhiro Goi, Fumino Iwata, Yoko Sugihara, Shingo Higa, Taiichiro Chikama |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |